Skip to main content

ACR/ARP 2019

2019 ACR/ARP Annual Meeting Highlights

All the breaking news and expert interviews from the 2019 ACR/ARP Annual Meeting, Atlanta, USA, November 10–13.

Conference overview

The 2019 ACR/ARP Annual Meeting highlights the latest research and clinical guidance in rheumatology, and encompasses a wide variety of themes, including:

Conference coverage

News reporting and interviews from the American College of Rheumatology’s Annual Meeting commenced on Sunday, November 10. You can keep up to date in a number of ways:

Key clinical trials from ACR/ARP 2019

Expert interviews from ACR/ARP 2019

13-11-2019 | Rheumatoid arthritis | Video | Article

Researcher comment: The NORD-STAR trial

Merete Hetland discusses the NORD-STAR trial findings comparing remission rates after active conventional versus biologic treatment in patients with early rheumatoid arthritis (3:52).  

13-11-2019 | Axial spondyloarthritis | Video | Article

Expert commentary: The COAST-X trial

Laura Coates talks about the COAST-X trial results, and explores how ixekizumab may fit into the treatment paradigm for nonradiographic axial spondyloarthritis (5:12).

13-11-2019 | Osteoarthritis | Video | Article

Researcher comment: The HOPE trial

Féline Kroon takes us through the results of the HOPE trial, demonstrating that short-term prednisolone treatment may be an option for patients with hand osteoarthritis experiencing a flare following withdrawal of nonsteroidal anti-inflammatory drugs (4:12).

Research news from ACR/ARP 2019

13-11-2019 | Behçet’s disease | ACR/ARP 2019 | News

Apremilast reduces oral ulcer burden in Behçet’s syndrome

The small molecule phosphodiesterase 4 inhibitor apremilast reduces the number of oral ulcers and improves quality of life to a greater degree than placebo in people with Behçet’s syndrome, results of the phase III RELIEF study show.

13-11-2019 | Systemic lupus erythematosus | ACR/ARP 2019 | News

TULIP-2 meets primary endpoint for anifrolumab efficacy in SLE

Anifrolumab has shown clinical efficacy in systemic lupus erythematosus, based on BICLA response as the primary outcome, TULIP-2 results show.

13-11-2019 | Axial spondyloarthritis | ACR/ARP 2019 | News

Secukinumab may represent a treatment option for nonradiographic axSpA

The PREVENT investigators have reported positive results for the IL-17A inhibitor secukinumab in patients with nonradiographic axial spondyloarthritis at the 2019 ACR/ARP Annual Meeting in Atlanta, Georgia, USA.

ACR/ARP 2019 pre-conference content

Key clinical trials at ACR/ARP 2019

Get up to speed on the clinical trials headlining ACR/ARP 2019 with our brief overviews.

Session recommendations

The Editorial and Advisory Board share their recommended sessions ahead of ACR/ARP 2019.

Image Credits